iBio (IBIO) vs Kazia Therapeutics (KZIA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
iBio (IBIO) has outperformed Kazia Therapeutics (KZIA) over the past year, losing 23.8% versus a loss of 41.1%. Over five years, KZIA leads with a -99.0% price change compared with -99.8% for IBIO. iBio is the larger company by market cap ($56.4 million vs $56.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IBIO | KZIA |
|---|---|---|
| Share price | $0.8001 | $4.92 |
| Market cap | $56.37M | $56.22M |
| 1-day change | -0.11% | -8.38% |
| YTD return | -58.54% | -28.59% |
| 1-year return | -23.80% | -41.08% |
| 5-year return | -99.76% | -99.01% |
| EPS (TTM) | $-0.27 | $-6.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $100.00K | — |
| Revenue growth (YoY) | -75.00% | — |
| Net income (latest FY) | $-33.04M | — |
| Operating margin | -35141.00% | — |
| Net margin | -33044.00% | — |
| 52-week high | $3.82 | $17.40 |
| 52-week low | $0.68 | $4.50 |
| Distance from 52-week high | -79.05% | -71.72% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +611.16% | +476.02% |
| Average volume | 678.91K | 307.30K |
| Shares outstanding | 70.46M | 11.43M |
| Employees | 23 | 6 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IBIO has outperformed KZIA by 17.3 percentage points over the past year.
About iBio
IBIO stock →iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large target proteins Its product pipelines for cardiometabolic disease area include IBIO-601, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody designed to inhibit myostatin and activin A signaling to preserve lean mass; IBIO-600 Myostatin Antibody, monoclonal antibody blocking myostatin that is in phase 1; Amylin Antibody, a pancreatic hormone that promotes satiety and appetite control through activation of the amylin receptor; CCR8, a Treg-targeting immunotherapy; and MUC16 antibodies.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
About Kazia Therapeutics
KZIA stock →Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
IBIO vs KZIA FAQ
Which is bigger, iBio or Kazia Therapeutics?
iBio (IBIO) is larger, with a market capitalization of $56.37M compared with $56.22M for Kazia Therapeutics (KZIA).
Which stock has performed better over the past year, IBIO or KZIA?
IBIO returned -23.80% over the past 12 months, compared with -41.08% for KZIA (price return, excluding dividends). Past performance does not predict future results.
Are iBio and Kazia Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.